Eluvixtamab Biosimilar – Anti-CD33;CD3E mAb – Research Grade

Eluvixtamab Biosimilar – Anti-CD33,CD3E mAb – Research Grade Introduction

Eluvixtamab Biosimilar is a novel monoclonal antibody (mAb) that targets both CD33 and CD3E, two important proteins involved in the immune response. This research grade antibody has shown promising results in pre-clinical studies and is currently being evaluated for its potential therapeutic applications.

Structure of Eluvixtamab Biosimilar

Eluvixtamab Biosimilar is a chimeric antibody, meaning it is composed of both human and mouse components. The variable region of the antibody is derived from a mouse mAb that specifically binds to CD33 and CD3E, while the constant region is humanized to reduce immunogenicity. This structure allows for high specificity and affinity towards the target proteins.

Mechanism of Action

Eluvixtamab Biosimilar works by binding to both CD33 and CD3E on the surface of immune cells. CD33 is a protein found on myeloid cells, such as monocytes and macrophages, while CD3E is a protein found on T cells. By binding to both proteins, Eluvixtamab Biosimilar brings these two types of immune cells in close proximity, leading to enhanced immune response and cell death of target cells.

Therapeutic Applications

Eluvixtamab Biosimilar has shown potential in the treatment of various diseases, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other hematological malignancies. CD33 is overexpressed on the surface of AML cells, making it an ideal target for this antibody. By binding to CD33, Eluvixtamab Biosimilar can induce cell death and inhibit the growth of AML cells. Additionally, the binding of Eluvixtamab Biosimilar to CD3E can activate T cells, leading to a stronger immune response against cancer cells.

Advantages of Eluvixtamab Biosimilar

Compared to other anti-CD33 antibodies, Eluvixtamab Biosimilar has several advantages. Its chimeric structure allows for high specificity and affinity towards the target proteins, while its humanized constant region reduces the risk of immunogenicity. Additionally, the ability to target both CD33 and CD3E makes it a more potent therapeutic agent compared to antibodies that only target one protein.

Conclusion

In conclusion, Eluvixtamab Biosimilar is a novel monoclonal antibody that targets both CD33 and CD3E, two important proteins involved in the immune response. Its unique structure and mechanism of action make it a promising therapeutic agent for the treatment of various diseases, particularly in the field of oncology. Further research and clinical trials are needed to fully evaluate the potential of Eluvixtamab Biosimilar in improving patient outcomes.